Litcius/Paper detail

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Pin Zhang, Qingyuan Zhang, Zhongsheng Tong, Tao Sun, Wěi Li, Quchang Ouyang, Xichun Hu, Ying Cheng, Min Yan, Yueyin Pan, Yuee Teng, Xi Yan, Ying Wang, Weimin Xie, Xiaohua Zeng, Xiaojia Wang, Chang-Lu Hu, Cuizhi Geng, Hongwei Zhang, Wenxin Li, Xinhong Wu, Jincai Zhong, Jingwei Xu, Yanxia Shi, Wenhua Wei, Nayima Bayaxi, Xiaoyu Zhu, Binghe Xu

2023The Lancet Oncology96 citationsDOI

Topics & Concepts

AnastrozoleLetrozoleMedicineInternal medicineBreast cancerOncologyFulvestrantMetastatic breast cancerPlaceboGoserelinClinical endpointProgression-free survivalTamoxifenCancerGynecologyRandomized controlled trialChemotherapyPathologyAlternative medicineAdvanced Breast Cancer TherapiesCancer-related Molecular PathwaysEstrogen and related hormone effects